Tamibarotene in combination with venetoclax and azacitidine in previously untreated adult patients selected for RARA-positive AML who are ineligible for standard induction therapy (SELECT AML-1) Meeting Abstract

  

Authors:	Stein, E.; De Botton, S.; Pigneux, A.; McMahon, C.; Ball, B.; Borthakur, G.; Eghtedar, A.; Kambhampati, S.; Tache, J.; Wang, E. S.; Kelley, H.; Volkert, A.; Baker, K.; Kang-Fortner, Q.; Madigan, C.; Warlick, E. D.; Roth, D. A.; Kell, M.; Pollyea, D. A.
Abstract Title:	Tamibarotene in combination with venetoclax and azacitidine in previously untreated adult patients selected for RARA-positive AML who are ineligible for standard induction therapy (SELECT AML-1)
Meeting Title:	2022 ASCO Annual Meeting
Journal Title:	Journal of Clinical Oncology
Volume:	40
Issue:	16 Suppl.
Meeting Dates:	2022 Jun 3-7
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2022-06-01
Language:	English
ACCESSION:	WOS:000863680305063
PROVIDER:	wos
DOI:	10.1200/JCO.2022.40.16_suppl.TPS7065
Notes:	Meeting Abstract: TPS7065 -- Meeting also held virtually -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/201570